News

The notes pay an 8% coupon, have a three year maturity and a conversion price of $2.65 a share. The aggregate net proceeds of the notes, after deducting

N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including cystic fibrosis and asthma. The primary endpoint of the study is patient safety

VantageCath is designed to significantly reduce exposure to bloodborne pathogens during the placement of the catheter and also provide the clinician with desirable feature sets. Existing safety engineered

The consideration is subject to adjustments based on ConvaTec’s audited 2007 financial statements and closing working capital. The closing, which is subject to customary regulatory approvals, is anticipated

Also investing in this financing were existing investors Galen Partners, Sycamore Ventures, Amkey Ventures, Lexli Investment, and Eminent Venture Capital. Cardiva also announced that Rick Anderson, a managing

The patent-pending modular forceps and accessories are designed to provide surgeons added comfort while reducing per-procedure costs through the reduction of inventory and obsolescence. The proprietary instruments offer

Under the company’s collaboration agreement with GlaxoSmithKline (GSK), Epix is entitled to receive a $7.5 million milestone payment from GSK related to the start of the Phase IIb

Lumenis ophthalmic unit has been streamlined to report to Gideon Sturlesi, who will lead the unit for the present time in addition to his role as Lumenis’s corporate

Adenuric (febuxostat) 80mg and 120mg tablets are indicated for the treatment of chronic hyperuricaemia for conditions in which urate deposition has already occurred (including a history, or presence